Finally, India may soon get treatment for the deadly Hepatitis C virus which afflicts possibly 12 million people in India.
About 11 Indian firms have been given licenses by its American manufacturer for the drug called Epclusa for treating the virus.
The medicine can be prescribed to anyone who tests positive for Hepatitis C, as it doesn’t require costly gene-type testing.
By taking one pill a day for 8-12 weeks, a person can be cured. ra Jacobson, MD, chairman of the Department of Medicine at Mount Sinai Beth Israel, New York told PTI:
“The approval of Epclusa represents an important step forward in the global effort to control and potentially eliminate HCV as it provides a safe, simple and effective cure for the majority of HCV-infected patients, regardless of genotype.”
To make the treatment affordable, Gilead Sciences along with its 11 partners in India, are pioneering a Voluntary Licensing model that transfers technology and Intellectual Property.
“This forward thinking strategy opened for these Indian companies the market across all of India for generic versions of these drugs, plus the market for 100 other countries,” an industry source told PTI.